FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04625907 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

1672

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma

Interventions

DRUG: Irinotecan
DRUG: Actinomycin D
DRUG: Doxorubicin
DRUG: Ifosfamide
DRUG: Vincristine
DRUG: Vinorelbine
DRUG: Cyclophosphamide
DRUG: Temozolomide
RADIATION: radiotherapy
DRUG: Regorafenib

Sponsor

University of Birmingham